Maze Therapeutics (MAZE) insider granted 48,000 options and 24,000 RSUs

Rhea-AI Filing Summary

Maze Therapeutics insider awarded stock options and RSUs. On March 2, 2026, a reporting person who is a 10% owner and serves as President, R&D & CMO received 48,000 stock options with an exercise price of $45.61 per share, expiring on March 1, 2036. These options vest monthly over four years, with the first 1/48 tranche on April 1, 2026, contingent on continued service.

The insider was also granted 24,000 restricted stock units, each representing one share of common stock. This RSU award vests in four equal annual installments, starting on March 1, 2027, also subject to continued service. Unvested RSUs either vest on schedule or are cancelled before vesting.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$45.61	03/02/2026		A		48,000		(1)	03/01/2036	Common Stock	48,000	$0	48,000	D
Restricted Stock Units	(2)	03/02/2026		A		24,000		(3)	(4)	Common Stock	24,000	$0	24,000	D

Explanation of Responses:

1. The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

3. The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

4. These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Maze Therapeutics (MAZE) report in this Form 4?

Maze Therapeutics reported an insider receiving 48,000 stock options and 24,000 restricted stock units. The options carry a $45.61 exercise price, while each RSU represents one share of common stock delivered upon future vesting and settlement, subject to continued service.

What are the key terms of the 48,000 stock options at Maze Therapeutics (MAZE)?

The 48,000 stock options have a $45.61 exercise price and expire on March 1, 2036. They vest monthly in 1/48 increments, starting April 1, 2026, conditioned on the reporting person’s continued service to Maze Therapeutics on each vesting date.

How do the 24,000 RSUs for Maze Therapeutics (MAZE) vest?

The 24,000 RSUs vest in four equal annual installments. The first 1/4 tranche vests on March 1, 2027, with the remaining tranches vesting on each one-year anniversary, as long as the reporting person continues serving Maze Therapeutics on each vesting date.

Does each RSU in the Maze Therapeutics (MAZE) grant equal one share?

Each restricted stock unit equals a contingent right to receive one share of Maze Therapeutics common stock. The shares are delivered upon settlement after the RSUs vest, provided the reporting person satisfies the continued service conditions described in the award terms.

Do the Maze Therapeutics (MAZE) RSUs have an expiration date?

The RSUs do not have a traditional expiration date; they either vest or are cancelled. If vesting conditions are met on scheduled dates, shares are delivered; otherwise, unvested RSUs terminate before vesting, as specified in the award description for this Form 4.

What is the role of the reporting person in Maze Therapeutics (MAZE)?

The reporting person is identified as a 10% owner and serves as President, R&D & CMO of Maze Therapeutics. This senior leadership role is disclosed alongside the equity awards detailed in the Form 4 insider transaction report filed with the SEC.